Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$3.22B
Close$
$55.30
53% upside
Current Fair Value
53% upsideUndervalued by 53% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.22 Billion |
|---|---|
| Enterprise Value | $3.13 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-6.29 |
| Beta | 0.34 |
| Outstanding Shares | 96,288,650 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.96 |
|---|---|
| PEG | 51.91 |
| Price to Sales | 6.02 |
| Price to Book Ratio | 36.14 |
| Enterprise Value to Revenue | 5.3 |
| Enterprise Value to EBIT | -6.13 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis